In the news

Dr. Brian Dunkin, chief medical officer, Endoscopy, and Mike Jones, SVP and president, Endoscopy, discuss how endoluminal surgery (ELS) products from the recent Apollo Endosurgery acquisition represent a step forward in gastrointestinal (GI) care.

If you’re looking to advance your career, Mary Beth Moynihan, senior vice president of market access and chief marketing officer, has three words for you: “You’re worth it.”

Boston Scientific’s market capitalization has grown nearly 10 times larger since Mike Mahoney joined as CEO in 2011. He shared key insights about corporate strategy at DeviceTalks Boston in May.

Eric Thépaut, executive vice president and president, Europe, Middle East and Africa, shares how digital education platforms, real-time and on-demand technologies and remote case support are being utilized to help patients.

Data supporting use of key Boston Scientific electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX™ Left Atrial Appendage Closure Device were presented at Heart Rhythm 2023, the annual meeting of the Heart Rhythm Society.

Camille Chang Gilmore, vice president, human resources, and global chief diversity, equity & inclusion officer, shares what she believes are the core elements in a successful DEI initiative and why creating a workplace that encourages empathetic, collaborative engagement is critical for the innovation that powers the medical device industry.

Boston Scientific’s new global chief medical officer is already well-known in cardiovascular device space circles. Dr. Ken Stein joined Boston Scientific in 2009 as SVP and chief medical officer of its Rhythm Management business. He became chief medical officer for the entire company on Feb. 13.

Clinical trials are an early step in device and therapy development which have significant impact on the types of products available to patients. Boston Scientific leaders share how the company is working to advance diversity in medical research.

Trevor Boylston had transitioned from female to male a decade before he started working at Boston Scientific. He shares reflections on how navigating the world of work can be enormously challenging for members of the transgender community and how he got involved in the company’s LGBTQ resource group.

Boston Scientific introduced the first U.S. Food and Drug Administration (FDA)-cleared single-use duodenoscope in 2019. Therefore, it is fitting that our first conversation in the Industry Perspective section of iGIE is with Michael Jones, senior vice president and president, Endoscopy for Boston Scientific.

Jenny Dandin is an R&D engineer at Boston Scientific. In a recent telephone interview with Career Communications Group, she shared a unique perspective from her experience as a female making her way as an engineer at a top medical device company.

Paudie O’Connor, senior vice president of supply chain, shares lessons learned from the last few years of macro supply chain challenges, and why Boston Scientific puts its people at the center.

Medical technology company Boston Scientific is among the organizations working to reverse the under-representation of women and people of color specifically Black patients, in clinical trials. Its aptly named Close the Gap program aims to level the medical playing field.

Boston Scientific Corp. scaled back some shifts at its facilities in Puerto Rico in light of travel advisories, a spokeswoman said. But its sites remain fully functional and the company expects operations to resume at normal levels once the storm subsides and travel advisories are lifted.

Brad Sorenson, executive vice president, Global Operations, and Paudie O’Connor, senior vice president of supply chain, discuss how supply chain has evolved in recent years, including strategic supplier relationships, resilience and continuity planning and sustainability.

Boston Scientific has been named one of Fast Company's Best Workplaces for Innovators for the third consecutive year—this year earning a callout as a best workplace for women.

Gail Beauregard, vice president of global total rewards at Boston Scientific, discusses how the company strives to create an organization where employees feel that they belong and can do their best work.

Camille Chang Gilmore, vice president, human resources and global chief diversity, equity and inclusion officer at Boston Scientific shares how the company’s diversity and inclusion efforts are promoting equity with its caring culture.

How has Boston Scientific evolved over the last decade? What is the difference between a leader and a manager? What does it mean to prioritize innovation? Charmain and CEO Mike Mahoney answers these questions and more during a sit down with DeviceTalks.

Boston Scientific’s WATCHMAN FLX™ is associated with fewer major adverse events and higher rates of success than its predecessor, according to an analysis of registry data by researchers at Yale School of Medicine. The study looked at 27,000 recipients of Boston Scientific’s first-generation WATCHMAN 2.5, and the same number of recipients of its successor WATCHMAN FLX. The rate of major in-hospital adverse events was 1.35% in the FLX arm and 2.4% in the Watchman 2.5 cohort.

Using information from a number of continuous data-stream sensors in implantable cardiac devices, Boston Scientific developed the HeartLogic Heart Failure Diagnostic, which can predict heart failure events on average 34 days before they happen. The algorithm alerts doctors of worsening conditions, allowing for earlier intervention and preventative action.

Boston Scientific has put forward real-world safety data gathered on its left atrial appendage occlusion device, the WATCHMAN FLX™. The latest data from Boston Scientific, which spanned more than 16,000 patients with atrial fibrillation not caused by heart valve problems who received the next-generation WATCHMAN FLX device, demonstrated favorable outcomes.

The COVID-19 pandemic has exacerbated the opioid epidemic, and the need for a broader menu of non-opioid treatment options has never been greater. Boston Scientific continues to invest in cutting-edge therapies to help patients and their doctors navigate the ever-changing pain management journey. The Boston Scientific WaveWriter Alpha™ Spinal Cord Stimulation System provides multiple therapy options that can be used in combination to help patients find relief.

Boston Scientific has spent approximately $1 billion buying stakes in about 50 companies globally through its ventures portfolio as a source for new innovation and potential mergers and acquisitions down the road. Since 2018, half of the 16 acquisitions the company completed went through Boston Scientific Ventures, including three of five acquisition targets in 2021.

Baptist Health cardiologist Salil Patel has performed the first procedure in Northeast Florida using the SYNERGY MEGATRON™ stent during a coronary procedure to eliminate blockages in a patient’s heart. The SYNERGY MEGATRON™ is designed for use in large proximal vessels and features architecture with increased strength as well as the ability to expand to 6.0mm in diameter and accommodate tapered vessels.